PURPOSE: Neurofibromatosis type 1 (NF1) is a genetic disorder with associated musculoskeletal abnormalities, tumors, and developmental delays. The purpose of this study was to investigate and characterize the motor proficiency of children with NF1. METHODS: Children with NF1 were assessed using the Bruininks-Oseretsky Test (BOT 2) instrument. The NF1 group scores were compared with age and sex-matched test norms. RESULTS: Twenty-six children participated in the study. The NF1 group had statistically significant lower scores (P < .05) for the total motor composite (Z = -1.62) and 7 of the 8 subtests. Nineteen percent (n = 5) scored in the average category, 54% (n = 14) scored in the below-average category, and 27% (n = 7) scored in the well-below-average category. CONCLUSIONS: Children with NF1 have significantly lower motor proficiency than the BOT 2 normative scores. The results indicate the BOT 2 is useful in identifying and characterizing delays in motor proficiency for children with NF1.
PURPOSE:Neurofibromatosis type 1 (NF1) is a genetic disorder with associated musculoskeletal abnormalities, tumors, and developmental delays. The purpose of this study was to investigate and characterize the motor proficiency of children with NF1. METHODS:Children with NF1 were assessed using the Bruininks-Oseretsky Test (BOT 2) instrument. The NF1 group scores were compared with age and sex-matched test norms. RESULTS: Twenty-six children participated in the study. The NF1 group had statistically significant lower scores (P < .05) for the total motor composite (Z = -1.62) and 7 of the 8 subtests. Nineteen percent (n = 5) scored in the average category, 54% (n = 14) scored in the below-average category, and 27% (n = 7) scored in the well-below-average category. CONCLUSIONS:Children with NF1 have significantly lower motor proficiency than the BOT 2 normative scores. The results indicate the BOT 2 is useful in identifying and characterizing delays in motor proficiency for children with NF1.
Authors: D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil Journal: JAMA Date: 1997-07-02 Impact factor: 56.272
Authors: T Tucker; C Schnabel; M Hartmann; R E Friedrich; I Frieling; H-P Kruse; V-F Mautner; J M Friedman Journal: J Med Genet Date: 2008-12-09 Impact factor: 6.318
Authors: J F Souza; R L F Passos; A C M Guedes; N A Rezende; L O C Rodrigues Journal: J Musculoskelet Neuronal Interact Date: 2009 Jan-Mar Impact factor: 2.041
Authors: Barbara A Johnson; Bruce Macwilliams; John C Carey; David H Viskochil; Jacques L D'Astous; David A Stevenson Journal: Hum Mov Sci Date: 2011-09-08 Impact factor: 2.161
Authors: Kate Sullivan; Jad El-Hoss; Kate G R Quinlan; Nikita Deo; Fleur Garton; Jane T C Seto; Marie Gdalevitch; Nigel Turner; Gregory J Cooney; Mateusz Kolanczyk; Kathryn N North; David G Little; Aaron Schindeler Journal: Hum Mol Genet Date: 2013-10-24 Impact factor: 6.150
Authors: Máximo Zimerman; Maximilian J Wessel; Jan E Timmermann; Sofia Granström; Christian Gerloff; Victor F Mautner; Friedhelm C Hummel Journal: EBioMedicine Date: 2015-09-01 Impact factor: 8.143
Authors: Bonita P Klein-Tasman; Alina M Colon; Natalie Brei; Faye van der Fluit; Christina L Casnar; Kelly M Janke; Donald Basel; Dawn H Siegel; Jasmine A Walker Journal: Int J Pediatr Date: 2013-11-19